DDInter1467 DDInter1676
Pimavanserin is an atypical antipsychotic indicated for the treatment of psychiatric disorders. Although the exact mechanism of action is unknown, it is thought that pimavanserin interacts with the serotonin receptors, particularly the 5-HT<sub>2A</sub> and HT<sub>2C</sub> receptors. Unlike other atypical antipsychotics, pimavanserin lacks inherent dopaminergic activity. In fact, pimavanserin is the first antipsychotic drug without D<sub>2</sub> blocking activity. Therefore, pimavanserin can be used to treat psychotic symptoms without causing extrapyramidal or worsening motor symptoms.[A232613,A232573] Pimavanserin is marketed under the trade name NUPLAZID and developed by Acadia Pharmaceuticals. It was approved by the FDA in April 2016 for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Pimavanserin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Pimavanserin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Zafirlukast
Pimavanserin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bosutinib
Pimavanserin {u} may lead to a major life threatening interaction when taken with {v} Toremifene
Pimavanserin {u} may lead to a major life threatening interaction when taken with {v} Vemurafenib
Pimavanserin may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Pimavanserin may cause a moderate interaction that could exacerbate diseases when taken with Zafirlukast
Pimavanserin may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib
Pimavanserin may lead to a major life threatening interaction when taken with Toremifene
Pimavanserin may lead to a major life threatening interaction when taken with Vemurafenib